



Prime Medicine to Present at Upcoming Investor Conferences

November 8, 2023

Cambridge, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today announced that company management will present at two upcoming investor conferences:

- **Stifel Healthcare Conference:** Fireside Chat by Keith Gottesdiener, M.D., President and Chief Executive Officer, on Tuesday, November 14, 2023, at 4:10 p.m. ET in New York, NY.
- **Jefferies London Healthcare Conference:** Fireside Chat by Jeremy Duffield, M.D., Ph.D., Chief Scientific Officer, on Thursday, November 16, 2023, at 1:30 p.m. GMT (8:30 a.m. ET) in London, UK.

Live audio webcasts of both presentations will be available under "Events & Presentations" in the News & Events section of the Company's website at www.primemedicine.com. Replays of each webcast will be available on the Prime Medicine website for 30 days following each presentation.

About Prime Medicine

Prime Medicine is a leading biotechnology Company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is leveraging its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated, one-time, potentially curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types.

Prime Medicine is currently progressing a diversified portfolio of eighteen programs initially focused on genetic diseases with a fast, direct path to treating patients or with a high unmet need because they cannot be treated using other gene-editing approaches. Over time, the Company intends to maximize Prime Editing's therapeutic potential and advance potentially curative therapeutic options to patients for a broad spectrum of diseases. For more information, please visit www.primemedicine.com.

© 2023 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE, the Prime Medicine logos, and PASSIGE are trademarks of Prime Medicine, Inc. All other trademarks referred to herein are the property of their respective owners.

Investor Contact

Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com

Media Contact

Dan Budwick, 1AB
dan@1ABmedia.com